Aliya Frederick
Neurology with Special Qualifications in Child Neurology · San Diego, CANPI 1548657992
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 80.3% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $5,441, more than ten times the $158 reported in 2019.
Across 80 payments — averaging $88.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- Neurelis, Inc.$350
- SK Life Science, Inc.$157
- Amgen$125
- Greenwich Biosciences, Inc.$119
- Acadia Pharmaceuticals Inc$107
- plus $537 from 13 others
Across 11 payments — averaging $7262.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$80K
What the payments were for
- Consulting fees$3,60051%
- Travel & lodging$1,02614%
- Food & beverage$2,45035%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 29 | $5,682 |
| Neurelis, Inc. | 18 | $350 |
| SK Life Science, Inc. | 2 | $157 |
| Amgen | 1 | $125 |
| Greenwich Biosciences, Inc. | 1 | $119 |
| Acadia Pharmaceuticals Inc | 4 | $107 |
| Teva Pharmaceuticals USA, Inc. | 1 | $101 |
| Immedica Pharma US, Inc. | 4 | $87 |
| Jazz Pharmaceuticals Inc. | 2 | $62 |
| Eisai Inc. | 2 | $46 |
| CSL Behring | 3 | $44 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Biocodex, Inc. | 2 | $41 |
| Aquestive Therapeutics, Inc. | 2 | $41 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $20 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$4,876
- Epidiolex$119
- Austedo XR$101
How this compares
$7,078 in reported general payments places this provider in the 75th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Other neurology with special qualifications in child neurology in San Diego
- Brittany PassiakSan Diego$90K
- Joseph GleesonSan Diego$69K
- John CrawfordSan Diego$27K
- Richard HaasSan Diego$27K
- Shifteh SattarSan Diego$21K
- Jennifer YangSan Diego$15K
- Doris TraunerSan Diego$15K
- Olivia Kim McManusSan Diego$11K
- Katherine LongardnerSan Diego$11K
- Michael ChezSacramento$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.